Close Menu

NEW YORK (GenomeWeb News) – Agilent Technologies and Molecular Discovery on Sunday announced a co-marketing agreement to provide an advanced metabolite identification platform to biopharmaceutical researchers.

Under the terms of the deal, Agilent's high-resolution liquid chromatography/mass spectrometry technology will be co-marketed with Molecular Discovery's Mass-MetaSite software "to enable superior identification and analysis of complex biological mixtures," the firms said in a joint statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.

Sep
09
Sponsored by
10x Genomics

Recent advances in spatially resolved transcriptomics have greatly expanded the knowledge of complex multicellular biological systems.